Key Insights

Highlights

Success Rate

97% trial completion (above average)

Published Results

17 trials with published results (18%)

Research Maturity

57 completed trials (60% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

2.1%

2 terminated out of 95 trials

Success Rate

96.6%

+10.1% vs benchmark

Late-Stage Pipeline

23%

22 trials in Phase 3/4

Results Transparency

30%

17 of 57 completed with results

Key Signals

17 with results97% success

Data Visualizations

Phase Distribution

76Total
Not Applicable (14)
P 1 (2)
P 2 (38)
P 3 (17)
P 4 (5)

Trial Status

Completed57
Unknown15
Recruiting11
Active Not Recruiting4
Not Yet Recruiting4
Terminated2

Trial Success Rate

96.6%

Benchmark: 86.5%

Based on 57 completed trials

Clinical Trials (95)

Showing 20 of 20 trials
NCT07209761Phase 3RecruitingPrimary

A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

NCT06192160Phase 2RecruitingPrimary

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

NCT04930744Phase 2Completed

Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)

NCT07467252Phase 2Not Yet RecruitingPrimary

AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT

NCT07268664Phase 3Not Yet Recruiting

Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BLMZ Chinese Cohort

NCT06905522Phase 3RecruitingPrimary

A PAN-USR TB Multi-Center Trial

NCT05807399Phase 2RecruitingPrimary

PanACEA - STEP2C -01

NCT06114628Phase 2RecruitingPrimary

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

NCT06199921Phase 2RecruitingPrimary

ATORvastatin in Pulmonary TUBerculosis

NCT04666311CompletedPrimary

Diagnostic Accuracy of CAD4TB and C-reactive Protein Assay as Triage Tests for Pulmonary Tuberculosis

NCT07186478Not ApplicableActive Not RecruitingPrimary

I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis

NCT04550832Phase 2Completed

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)

NCT02333799Phase 3CompletedPrimary

A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB

NCT06649721Phase 3Active Not Recruiting

Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BDLL Chinese Cohort

NCT07076225Phase 3Not Yet RecruitingPrimary

Ultra-Short Regimen for Elderly DS-TB

NCT06922916Not Yet Recruiting

Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study

NCT04260477Phase 3Recruiting

Novel Triple-dose Tuberculosis Retreatment Regimen

NCT06081361Phase 3Active Not RecruitingPrimary

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis:Contezolid, Delamanid and Bedaquiline Cohort

NCT06528418Recruiting

Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath

NCT06727864Phase 3RecruitingPrimary

Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial

Scroll to load more

Research Network

Activity Timeline